Arrowhead Pharmaceuticals (ARWR) is up 4.2% today. Here is some analysis on what might have caused this price movement. ([arrowheadpharma.gcs-web.com](https://arrowheadpharma.gcs-web.com/static-files/daf5caf3-bd23-4d29-86fe-7543f3e1ebb3))
Analysis: The most likely driver appears to be a rebound after a sharp recent pullback, helped by fresh bullish analyst initiation and investor focus on several second-half 2026 pipeline catalysts. There does not appear to be a single major same-day corporate announcement, so part of today’s move could be investors repositioning around upcoming data and commercialization milestones. ([trefis.com](https://www.trefis.com/data/companies/ARWR?from=ARWR_streak_loss_2026-07-17&mod=co_top_arrowheadpharmaceuticals))
Details:
Stifel initiated coverage on July 14 with a Buy rating and a $98 price target, adding supportive sentiment around the stock. ([benzinga.com](https://www.benzinga.com/quote/ARWR/analyst-ratings?utm_source=openai))Management said in May that Phase 3 SHASTA-3 and SHASTA-4 top-line data for plozasiran in severe hypertriglyceridemia are expected in the third quarter of 2026. ([arrowheadpharma.gcs-web.com](https://arrowheadpharma.gcs-web.com/static-files/daf5caf3-bd23-4d29-86fe-7543f3e1ebb3))Management also highlighted expected Q3 data for ARO-DIMER-PA and late-Q3 or early-Q4 data for ARO-MAPT, reinforcing a catalyst-rich second half of the year. ([arrowheadpharma.gcs-web.com](https://arrowheadpharma.gcs-web.com/static-files/daf5caf3-bd23-4d29-86fe-7543f3e1ebb3))The company’s June cardiometabolic webinar and related materials emphasized that multiple milestones in the second half of 2026 could be transformative for the franchise, which may be helping sentiment recover after the recent slide. ([arrowheadpharma.com](https://arrowheadpharma.com/en-us/newsroom/arrowhead-pharmaceuticals-host-webinar-its-cardiometabolic))Sources:
Arrowhead Pharmaceuticals, Benzinga, MarketBeat
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ARWR Insider Trading Activity
$ARWR insiders have traded $ARWR stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
- JAMES C HAMILTON (Chief Medical Officer) has made 0 purchases and 2 sales selling 20,000 shares for an estimated $1,391,900.
- DANIEL JOSEPH APEL (Chief Financial Officer) has made 0 purchases and 3 sales selling 13,095 shares for an estimated $934,285.
- HONGBO LU sold 2,970 shares for an estimated $228,333
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EARLY ACCESS
Receive ARWR Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$ARWR Hedge Fund Activity
We have seen 241 institutional investors add shares of $ARWR stock to their portfolio, and 150 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,157,063 shares (-14.8%) from their portfolio in Q1 2026, for an estimated $197,947,850
- SLATE PATH CAPITAL LP removed 2,523,500 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $158,223,450
- FRED ALGER MANAGEMENT, LLC added 1,509,496 shares (+82.4%) to their portfolio in Q1 2026, for an estimated $94,645,399
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,500,828 shares (-71.9%) from their portfolio in Q1 2026, for an estimated $94,101,915
- VESTAL POINT CAPITAL, LP added 1,375,000 shares (+152.8%) to their portfolio in Q1 2026, for an estimated $86,212,500
- HOOD RIVER CAPITAL MANAGEMENT LLC added 1,056,534 shares (+inf%) to their portfolio in Q1 2026, for an estimated $66,244,681
- RENAISSANCE TECHNOLOGIES LLC added 1,036,495 shares (+inf%) to their portfolio in Q1 2026, for an estimated $64,988,236
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ARWR Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 8 analysts offer price targets for $ARWR in the last 6 months, with a median target of $89.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $100.0 on 07/01/2026
- Keay Nakae from Chardan Capital set a target price of $90.0 on 06/30/2026
- Mani Foroohar from Leerink Partners set a target price of $72.0 on 06/17/2026
- William Pickering from Bernstein set a target price of $46.0 on 05/13/2026
- Luca Issi from RBC Capital set a target price of $87.0 on 05/08/2026
- Brian Cheng from JP Morgan set a target price of $88.0 on 05/01/2026
- Michael Ulz from Morgan Stanley set a target price of $100.0 on 04/21/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Arrowhead Pharmaceuticals Gains as Investors Revisit Recent Bullish Coverage and Upcoming Pipeline Catalysts
Arrowhead Pharmaceuticals (ARWR) is up 4.2% today. Here is some analysis on what might have caused this price movement. ([arrowheadpharma.gcs-web.com](https://arrowheadpharma.gcs-web.com/static-files/daf5caf3-bd23-4d29-86fe-7543f3e1ebb3))
Analysis: The most likely driver appears to be a rebound after a sharp recent pullback, helped by fresh bullish analyst initiation and investor focus on several second-half 2026 pipeline catalysts. There does not appear to be a single major same-day corporate announcement, so part of today’s move could be investors repositioning around upcoming data and commercialization milestones. ([trefis.com](https://www.trefis.com/data/companies/ARWR?from=ARWR_streak_loss_2026-07-17&mod=co_top_arrowheadpharmaceuticals))
Details:
Sources:
Arrowhead Pharmaceuticals, Benzinga, MarketBeat
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ARWR Insider Trading Activity
$ARWR insiders have traded $ARWR stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ARWR Hedge Fund Activity
We have seen 241 institutional investors add shares of $ARWR stock to their portfolio, and 150 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ARWR Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 8 analysts offer price targets for $ARWR in the last 6 months, with a median target of $89.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »